
Waking up frequently at night to urinate or noticing a weaker urine stream is a common health concern for men as they age. When the prostate enlarges and presses against the urethra, it causes lower urinary tract symptoms such as frequent urination, a sensation of incomplete emptying, and nocturia (disrupted sleep due to nighttime urination). While benign prostatic hyperplasia (BPH) is not an immediate life-threatening disease, it can severely disrupt sleep quality and daily activities.
To address these challenges globally, Dongkook Pharmaceutical is set to introduce its newly formulated BPH combination therapy to the Latin American market.
Dongkook Pharmaceutical announced on July 2 that it has signed an exclusive license and supply agreement with Spanish pharmaceutical company Faes Farma for its BPH treatment, Uresco tablets. The 10-year contract covers 13 Latin American nations, including major markets such as Mexico, Colombia, Ecuador, Peru, and Chile.
The total value of the agreement is projected to reach up to 39 billion won over the next decade. The deal structure features an upfront payment, milestone payments tied to regulatory approvals and sales performance, and a long-term revenue-sharing model. Under the agreement, the two companies will divide operational responsibilities: Dongkook Pharmaceutical will manufacture and supply the finished Uresco tablets, while Faes Farma will manage the regulatory approval processes and commercial sales within each local market.
Navigating the diverse regulatory landscapes and distribution networks across Latin America independently can present significant hurdles for South Korean pharmaceutical firms. Partnering with an established entity like Faes Farma—which operates direct subsidiaries and robust marketing networks across Europe and Latin America—significantly eases the logistical burdens of entry. Faes Farma has designated urology as a core strategic therapeutic area in Latin America and plans to integrate Uresco into its specialty prescription portfolio to initiate country-by-country rollouts sequentially.
The Innovation Behind a Dual-Action Combination Therapy
Uresco tablets represent an innovative approach to BPH management by combining two proven active ingredients—dutasteride (0.5 mg) and tadalafil (5 mg)—into a single, fixed-dose daily pill. Dutasteride works progressively to reduce the physical volume of the enlarged prostate, while tadalafil targets muscle relaxation to rapidly improve immediate urinary symptoms like weakened streams and frequency. While physicians have historically co-prescribed these medications based on patient needs, combining them into a single tablet increases patient compliance and convenience by reducing the burden of taking multiple separate pills.
According to clinical review reports from the Ministry of Food and Drug Safety, Uresco is indicated for treating moderate-to-severe symptoms of BPH. In a 48-week Phase 3 clinical trial conducted across 19 hospitals in South Korea, patients taking the combination tablet demonstrated a significantly greater improvement in their International Prostate Symptom Score (IPSS) compared to groups taking either dutasteride or tadalafil as a monotherapy.
However, Uresco is a prescription-only medication that requires close medical supervision. Physicians must carefully evaluate a patient's overall health condition, including blood pressure, existing drug regimens, and liver or kidney function, before prescribing. In particular, the tadalafil component requires strict caution when co-administered with certain cardiovascular medications, such as nitrates.
Accelerating Long-Term Global Expansion
Dongkook Pharmaceutical designed Uresco to simultaneously target prostate volume reduction and rapid symptom relief, aiming directly at an estimated 830 billion won global market for BPH combination therapies, of which Latin America accounts for roughly 300 billion won. Following this contract, the company plans to secure additional agreements in other major regional markets, including Brazil.
"This entry into Latin America represents the first major milestone in accelerating the global commercialization of our dutasteride-tadalafil combination product line," a Dongkook Pharmaceutical official stated. "We will leverage this opportunity to build a sustainable business foundation in the global BPH market and continue demonstrating our core product competitiveness."
Beyond Uresco, Dongkook Pharmaceutical plans to expand its global reach by exporting alternative high-value products, including long-acting microsphere injectable formulations and liposome-based antifungal treatments developed through its proprietary drug delivery system (DDS) platform technology. This initial agreement is expected to serve as a strategic framework for future international partnerships built on the company's advanced drug modification and delivery capabilities.
